Exploring Novel Therapies for Scleroderma-Associated ILD: An Evidence-based Approach to Diagnosis and Management

Release date: October 10, 2018
Expiration date: October 10, 2019
Estimated Time to Complete Activity: 0.75 Hour(s)



Aryeh Fischer, MD
Associate Professor of Medicine
Division of Rheumatology
Division of Pulmonary Sciences &
Critical Care Medicine
Department of Medicine
University of Colorado School of Medicine
Aurora, Colorado


David Lederer, MD
Associate Professor
Department of Medicine
Associate Division Chief
Clinical & Translational Research Director
Advanced Lung Disease Program
Columbia University
New York, New York


ILD is universally recognized as the most serious complication of SSc and has been identified as the leading cause of mortality among patients with SSc-ILD. Despite awareness of the risk for ILD development among patients with SSc, prompt and accurate diagnosis remains challenging due to the lack of accepted protocols for screening and risk stratification, as well as difficulties in distinguishing between systemic manifestations of SSc and exertional dyspnea due to lung involvement.

Traditional treatment approaches have centered upon immunosuppression to target underlying inflammation and autoimmunity. However, with the advent of antifibrotic therapies capable of slowing, or even halting, the progression of IPF, questions have been raised about their potential to similarly impact SSc-ILD progression. While it remains to be determined whether this is indeed the case, studies to address this issue are ongoing. This program will provide clinicians with education that is targeted at helping them to remain informed regarding the current status of these investigations, as well as provide them with the knowledge and skills to provide patients with SSc-ILD with an accurate diagnosis and optimal disease management


This educational initiative has been designed for pulmonologists, rheumatologists, and internal medicine physicians involved in the care of patients with SSc-ILD

  • Determine the elements of a comprehensive diagnostic workup to achieve timely diagnosis of SSc-ILD and assess patient risk for disease progression
  • Tailor treatment approaches for patients with SSc-ILD based on relevant clinical trial evidence of investigational regimens
  • Outline effective strategies for improving the physician-patient dialogue and collaboration across the multidisciplinary care team to meet the needs of patients with SSc-ILD

There are no fees for participating and receiving CME credit for this activity. During the period of October 10, 2018 through October 10, 2019 participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.




Integrity Continuing Education is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.


Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.


For information about the ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or via email at information@integrityce.com.


Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Aryeh Fischer, MD
Consulting Fees: Boehringer Ingelheim, F Hoffman La Roche

David Lederer, MD
Consulting Fees: Roche, Veracyte
Research: Boehringer Ingelheim

Michelle Rizzo, ELS, hereby states that she of her spouse/life partner do not have financial relationships to products of devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

The Integrity CE planners and managers have nothing to disclose.


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Boehringer Ingelheim Pharmaceuticals, Inc. do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and…(continued)


Windows 98, 2000, XP, 2003, Vista, and 7
Internet Explorer 6/7
Firefox 2
Mozilla 1.7 or higher
Netscape 8.1 or higher
Flash Player 10

Mac OS X 10.3, 10.4
Safari 1.3 (Mac OS 10.3)
Safari 2.0 or higher (Mac OS 10.4)
Firefox 2
Flash Player 10

Use of Internet Explorer browser is not recommended.

Click here for more information on minimum system requirements.


The information provided in this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.


This CME activity is provided by Integrity Continuing Education.


This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Continue to Pretest